

# BIBR 1532

Catalog No: tcsc0902



## Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



## Specifications

**CAS No:**

321674-73-1

**Formula:**

$C_{21}H_{17}NO_3$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

Telomerase

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 100$  mg/mL (301.79 mM)

**Observed Molecular Weight:**

331.36


## Product Description

BIBR 1532 is a potent, selective and non-competitive **telomerase** inhibitor with **IC<sub>50</sub>** of 100 nM in a cell-free assay.

IC50 & Target: IC50: 100 nM (telomerase)

***In Vitro:***

BIBR 1532 non-competitively inhibits telomerase activity<sup>[1]</sup>. BIBR 1532 inhibits the proliferation of JVM13 leukemia cells with an IC<sub>50</sub> of 52 μM, and similar effect also occurs in other leukemia cell lines such as Nalm-1, HL-60, and Jurkat. BIBR 1532 exerts antiproliferative effect on acute myeloid leukemia (AML) with IC<sub>50</sub> of 56 μM with no effect on the proliferative capacity of normal hematopoietic progenitor cells<sup>[2]</sup>. BIBR 1532 (2.5 μM) reduces colony-forming ability, induces telomere length shortening and causes chemotherapeutic sensitization via inhibiting telomerase activity in MCF-7/WT and melphalan-resistant MCF-7/MInR cell lines<sup>[3]</sup>. BIBR 1532 is cytotoxic in a dose-dependent manner in T-cell prolymphocytic leukemia (T-PLL)<sup>[4]</sup>. BIBR 1532 in combination with carboplatin (a chemotherapeutic agent) eliminates ovarian cancer spheroid-forming cells in ES2, SKOV3, and TOV112D cell lines<sup>[5]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!